Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. The antithrombotic course follows her from admission to her 12-month visit; each trial answers one decision in her care.
This page helps you decide: Would prasugrel have been a sound choice for her, at 77?
After this page you can
Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.
For Mrs. K., prasugrel at the dose TRITON tested would not have been a sound choice: at 77 she belongs to the group in which net clinical outcome was 19.5% vs 19.7%, with a trend to more major bleeding (4.1% vs 3.4%), and the label's exception (diabetes or prior MI) does not cover her. Ticagrelor, which she received, is the sheet's other COR 1 choice; whether reduced-dose prasugrel changes this is the next page, ISAR-REACT 5. On the one-pager TRITON sits on page 1, in the “Which P2Y12 inhibitor?” box (Prasugrel limits row).